Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

Brinsupri is a first-in-class DPP1 inhibitor that has been found to inhibit activation of neutrophil enzymes that drive chronic airway inflammation in non-cystic fibrosis bronchiectasis.

The FDA granted approval to brensocatib for treating adults and children aged at least 12 years with non-cystic fibrosis ...

The FDA has approved oral brensocatib (Brinsupri) for adults and children 12+ with non-cystic fibrosis bronchiectasis. As a ...

Brensocatib (Brinsupri; Insmed) gains FDA approval as the first treatment for bronchiectasis, offering hope to patients with ...

Insmed has received FDA clearance for the first treatment for a chronic lung disease, opening the biotech up to what could be ...

InsmedINSM stock hit a record high Tuesday after the Food and Drug Administration approved its drug, brensocatib, for ...

Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...

Insmed Incorporated's Q2 2024 revenue grew by 17% year-over-year, reaching $90.3 million, driven by strong ARIKAYCE sales. The company is preparing for the U.S. launch of brensocatib in mid-2025 ...

He points out that Insmed’s brensocatib has shown a significant reduction in exacerbation risk and is closer to market launch, with no approved therapies currently available for bronchiectasis.